Critical to the evaluation of potential therapeutics (pharmacological, gene or cell therapies) in mouse modelsof muscular dystrophy are sensitive and repeatable physiological assessments of muscle function.Therefore, we are proposing to create a research core which performs ex vivo, in situ, and whole animalassessments of muscle integrity and function. Three of the projects (Projects 1-3) proposed in this grantcontain components that require muscle physiological measurements. (Project 4 relies on the outcome ofthese tests for pre-clinical justification.) The Physiological Assessment Core will meet the needs of theprojects within this grant, as well as the needs of the muscular dystrophy research community. In addition,the core will maintain in house colonies of mouse models of DMD, LGMD, and myotonic dystrophy in orderto support studies where long-term testing is necessary. The resources of this core are contained within Dr.Sweeney's laboratory, which includes all instrumentation for muscle physiological measurements, as well asspecialized equipment for hindlimb suspension experiments, documented free wheel running, and treadmillrunning. Dr. Barton is a muscle physiologist with extensive experience evaluating muscle function in mice.Monica Zadel is an expert at performing muscle mechanical experiments, while Pedro Acosta maintains ourbreeding colonies and will monitor hindlimb suspension and free wheel running experiments.We believe that this Core will provide a valuable resource that will enable the entire muscular dystrophyresearch community to utilize these assays to assess the potential benefits of a large number of approachesto the treatment of different forms of muscular dystrophy

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54AR052646-04
Application #
7648214
Study Section
Special Emphasis Panel (ZNS1)
Project Start
2008-06-01
Project End
2010-05-31
Budget Start
2008-06-01
Budget End
2009-05-31
Support Year
4
Fiscal Year
2008
Total Cost
$186,049
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Barthélémy, Florian; Defour, Aurélia; Lévy, Nicolas et al. (2018) Muscle Cells Fix Breaches by Orchestrating a Membrane Repair Ballet. J Neuromuscul Dis 5:21-28
Smith, Lucas R; Barton, Elisabeth R (2018) Regulation of fibrosis in muscular dystrophy. Matrix Biol 68-69:602-615
Hicks, Michael R; Hiserodt, Julia; Paras, Katrina et al. (2018) ERBB3 and NGFR mark a distinct skeletal muscle progenitor cell in human development and hPSCs. Nat Cell Biol 20:46-57
Barnard, Alison M; Willcocks, Rebecca J; Finanger, Erika L et al. (2018) Skeletal muscle magnetic resonance biomarkers correlate with function and sentinel events in Duchenne muscular dystrophy. PLoS One 13:e0194283
Fallon, Justin R; McNally, Elizabeth M (2018) Non-Glycanated Biglycan and LTBP4: Leveraging the extracellular matrix for Duchenne Muscular Dystrophy therapeutics. Matrix Biol 68-69:616-627
Batra, Abhinandan; Harrington, Ann; Lott, Donovan J et al. (2018) Two-Year Longitudinal Changes in Lower Limb Strength and Its Relation to Loss in Function in a Large Cohort of Patients With Duchenne Muscular Dystrophy. Am J Phys Med Rehabil 97:734-740
Daniel, Bence; Nagy, Gergely; Czimmerer, Zsolt et al. (2018) The Nuclear Receptor PPAR? Controls Progressive Macrophage Polarization as a Ligand-Insensitive Epigenomic Ratchet of Transcriptional Memory. Immunity 49:615-626.e6
Willcocks, Rebecca J; Triplett, William T; Lott, Donovan J et al. (2018) Leg muscle MRI in identical twin boys with duchenne muscular dystrophy. Muscle Nerve :
Aartsma-Rus, Annemieke; Ferlini, Alessandra; McNally, Elizabeth M et al. (2018) 226th ENMC International Workshop:: Towards validated and qualified biomarkers for therapy development for Duchenne muscular dystrophy 20-22 January 2017, Heemskerk, The Netherlands. Neuromuscul Disord 28:77-86
McNally, Elizabeth M; Wyatt, Eugene J (2017) Mutation-Based Therapy for Duchenne Muscular Dystrophy: Antisense Treatment Arrives in the Clinic. Circulation 136:979-981

Showing the most recent 10 out of 142 publications